Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer.

Authors

null

G. Somlo

City of Hope, Duarte, CA

G. Somlo , S. M. Li , X. Wu , S. Lau , P. H. Frankel , L. Kruper , H. Gao , G. Sun , J. H. Yim , A. Hurria , J. E. Mortimer , F. De Snoo , I. B. Paz , J. Rossi , E. Wang , P. Roepman , Y. Yen , L. van't Veer , R. A. Bender

Organizations

City of Hope, Duarte, CA, City of Hope Cancer Center/Beckman Research Institute, Duarte, CA, Agendia, Amsterdam, Netherlands, University of California, San Francisco, San Francisco, CA, Agendia, Inc., Irvine, CA

Research Funding

Other

Background: Gene expression profiling may predict for pathologic complete response (pCR) after neoadjuvant therapy (NT). Identification of both miRNA and gene expression may yield novel targets and improved NT. Methods: Patients (pts) with HER2- locally advanced/inflammatory breast cancer (BC) were randomized to receive docetaxel, doxorubicin, cyclophosphamide (TAC, arm A), or A and C given every 2 weeks x 4, followed by carboplatin and nab-paclitaxel (arm B). Pts with HER2+ BC received NT similar to arm B, with trastuzumab (arm C). Core biopsies were snap-frozen prior to NT, and RNA was extracted for gene array analysis (MammaPrint, BluePrint: basal, luminal, and HER2 profiling, and Agilent 44K microarray), and for deep sequence miRNA analysis with the Solexa/Illumina platform. Pathological assessment included grade, ER, HER2 expression, and evidence of residual BC vs.pCR. Unsupervised hierarchical clustering analysis and Fisher’s exact tests were utilized to assess for correlation between miRNA and gene expression, and pathologic assessment. Significant analysis of microarrays (SAM) was used to identify miRNAs differentially expressed and predictive for response (pCR vs. other) to NT. Results: miRNA expression was measured in 72 of 119 enrolled pts; 487 of the 882 miRNAs sequenced, were expressed with raw counts of > 10 in at least 3 pts. miRNA expression patterns revealed three distinct pt clusters, which were significantly associated with the 3 BluePrint subtypes and ER status (Fisher’s exact test, P-values < 1e-5), and moderately associated with HER2 status and MammaPrint classes at borderline significance (P-value: 0.08 and 0.05). SAM identified 6 up and 9 down-regulated miRNAs associated with pCR in HER2- patients (N=43, 4 pCRs) with ≥2 fold changes at false discovery rate (FDR) < 10%. No significant signals of miRNA expression associated with pCR were found in HER2+ pts (N=28; 13 pCRs) at the same FDR level. Conclusions: Combined assessment of miRNA and gene expression patterns is feasible, and pending validation, may yield information leading to individualized and improved NT.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT00295893

Citation

J Clin Oncol 29: 2011 (suppl; abstr 548)

Abstract #

548

Poster Bd #

2E

Abstract Disclosures